InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.505 -0.005 (-0.98%)+
Announcement
Release
30 Jul 2026 10:00AM
Price at Release
$0.510
Full Release
download
Summary
Alterity Therapeutics Limited issued its Q4 FY26 Quarterly Activities and Appendix 4C Cash Flow Report highlighting significant progress in the regulatory pathway for ATH434, a treatment for Multiple System Atrophy (MSA). The FDA confirmed a registrational pathway for ATH434, agreeing that a single pivotal Phase 3 trial plus confirmatory evidence could support approval. The company plans to initiate Phase 3 trial activities by year-end 2026. Financially, the company reported A$37.3 million in cash as of June 30, 2026, with a notable A$3.98 million tax refund received shortly after the quarter ended. The report also detailed cash flows, governance changes, and ongoing strategic funding evaluations.
Key Points
  • Positive FDA End-of-Phase 2 meeting for ATH434.
  • Planned initiation of Phase 3 trial by end of 2026.
  • Received A$3.98 million R&D Tax Incentive refund.
  • Cash balance of A$37.3 million as of June 30, 2026.
  • Strategic funding and partnership evaluations ongoing.
  • Ms Ann Cunningham appointed to Board of Directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.